RNA synthesis initiates in vitro conversion of M13 DNA to its replicative form.
Soluble enzyme fractions from uninfected Escherichia coli convert M13 and varphiX174 viral single strands to their double-stranded replicative forms. Rifampicin, an inhibitor of RNA polymerase, blocks conversion of M13 single strands to the replicative forms in vivo and in vitro. However, rifampicin does not block synthesis of the replicative forms of varphiX174 either in vivo or in soluble extracts. The replicative form of M13 synthesized in vitro consists of a full-length, linear, complementary strand annealed to a viral strand. The conversion of single strands of M13 to the replicative form proceeds in two separate stages. The first stage requires enzymes, ribonucleoside triphosphates, and single-stranded DNA; the reaction is inhibited by rifampicin. The macromolecular product separated at this stage supports DNA synthesis with deoxyribonucleoside triphosphates and a fresh addition of enzymes; ribonucleoside triphosphates are not required in this second stage nor does rifampicin inhibit the reaction. We presume that in the first stage there is synthesis of a short RNA chain, which then primes the synthesis of a replicative form by a DNA polymerase.
D000645:Ammonium Sulfate; D003090:Coliphages / Q000378:metabolism; D004261:DNA Replication / Q000187:drug effects*; D004277:DNA, Single-Stranded / Q000378:metabolism; D004279:DNA, Viral / Q000096:biosynthesis*; D004926:Escherichia coli / Q000201:enzymology; D009690:Nucleic Acid Conformation; D012316:RNA Nucleotidyltransferases / Q000378:metabolism; D012367:RNA, Viral / Q000096:biosynthesis*; D012293:Rifampin / Q000494:pharmacology
D004277:DNA, Single-Stranded; D004279:DNA, Viral; D012367:RNA, Viral; D012316:RNA Nucleotidyltransferases; D000645:Ammonium Sulfate; D012293:Rifampin